Session » RA – Treatment Poster III
- 10:30AM-12:30PM
-
Abstract Number: 2267
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2253
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
- 10:30AM-12:30PM
-
Abstract Number: 2254
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers
- 10:30AM-12:30PM
-
Abstract Number: 2269
Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
- 10:30AM-12:30PM
-
Abstract Number: 2281
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
- 10:30AM-12:30PM
-
Abstract Number: 2275
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
- 10:30AM-12:30PM
-
Abstract Number: 2286
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
- 10:30AM-12:30PM
-
Abstract Number: 2283
Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
- 10:30AM-12:30PM
-
Abstract Number: 2257
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
- 10:30AM-12:30PM
-
Abstract Number: 2282
Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
- 10:30AM-12:30PM
-
Abstract Number: 2256
Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
- 10:30AM-12:30PM
-
Abstract Number: 2280
Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)
- 10:30AM-12:30PM
-
Abstract Number: 2255
Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective
- 10:30AM-12:30PM
-
Abstract Number: 2279
Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
- 10:30AM-12:30PM
-
Abstract Number: 2259
Effects of Anti-Obesity Medications in RA Patients
- 10:30AM-12:30PM
-
Abstract Number: 2274
Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
- 10:30AM-12:30PM
-
Abstract Number: 2272
Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry
- 10:30AM-12:30PM
-
Abstract Number: 2266
Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2271
Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial
- 10:30AM-12:30PM
-
Abstract Number: 2252
Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
- 10:30AM-12:30PM
-
Abstract Number: 2270
Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country
- 10:30AM-12:30PM
-
Abstract Number: 2265
Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
- 10:30AM-12:30PM
-
Abstract Number: 2284
Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
- 10:30AM-12:30PM
-
Abstract Number: 2261
Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 2285
Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol
- 10:30AM-12:30PM
-
Abstract Number: 2278
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
- 10:30AM-12:30PM
-
Abstract Number: 2260
Statin Use in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis: Are RA Patients More Likely to Receive Statins?
- 10:30AM-12:30PM
-
Abstract Number: 2277
Switching to a Targeted Drug with a Different Mode of Action After Discontinuation of the First TNF Inhibitor Is Associated with Better Drug Survival Compared to a Second TNF Inhibitor in Rheumatoid Arthritis: A Propensity Score-matched Analysis from the Czech ATTRA Registry
- 10:30AM-12:30PM
-
Abstract Number: 2268
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
- 10:30AM-12:30PM
-
Abstract Number: 2263
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
- 10:30AM-12:30PM
-
Abstract Number: 2264
The Risk of Malignancy and Major Adverse Cardiovascular Events with the Use of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Real-World Evidence
- 10:30AM-12:30PM
-
Abstract Number: 2258
The Window of Opportunity: A Concept Also Applicable to Undifferentiated Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2273
Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study
- 10:30AM-12:30PM
-
Abstract Number: 2276
Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
- 10:30AM-12:30PM
-
Abstract Number: 2262
Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients